Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The effectiveness of sildenafil citrate in patients with erectile dysfunction and lower urinary system symptoms and the significance of asymptomatic inflammatory prostatitis

International Journal of Impotence Research volume 22, pages 349–354 (2010)Cite this article

Subjects

Abstract

We evaluated the effectiveness of sildenafil citrate on lower urinary system symptoms (LUTS) by using symptom score scales. We also evaluated whether or not the presence of asymptomatic inflammatory prostatitis had an effect on the alteration in the symptom scores. A total of 36 male patients were included in the study. For all the cases, ‘International Prostate Symptom Score’ (IPSS), ‘National Health Institute Chronic Prostatitis Symptom Index’ (NIH-CPSI) and ‘International Index of Erectile Function’ (IIEF-5) were investigated and the scores were calculated in the first visit. Sildenafil citrate was given for 30 days and at the second visit IPSS, NIH-CPSI and IIEF-5 scores were once more analyzed. Afterwards, the alterations of the scores between visits were statistically compared. Mean age of the 36 cases included in the study was 59.03±1.35. When the alterations in parameters of first visit and second visit were evaluated, we found a statistically significant increase in IIEF-5 and a statistically significant decrease in IPSS, IPSS-QOL (Quality of Life). In addition, when the cases were divided into two groups with and without asymptomatic inflammatory prostatitis, in the cases with asymptomatic inflammatory prostatitis, sildenafil citrate caused improvement only in ED, but had no effect on LUTS. Sildenafil citrate use in cases with LUTS and ED has an improving effect on LUTS as well as ED. However, in cases with asymptomatic inflammatory prostatitis, sildenafil citrate did not lead to an improvement in LUTS.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637–649.

    Article  Google Scholar 

  2. Costabile RA, Steers WD . How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 2006; 3: 676–681.

    Article  Google Scholar 

  3. Wang C . Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol 2010; 20: 49–54.

    Article  Google Scholar 

  4. Carson CC . Combination of phosphodiesterase-5 inhibitors and alfa-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 2006; 97: 39–43.

    Article  CAS  Google Scholar 

  5. Marszalek M, Wehrberger C, Hochreiter W, Temml C, Madersbacher S . Symptoms suggestive of chronic pelvic pain syndrome in an urban population: prevalence and associations with lower urinary tract symptoms and erectile function. J Urol 2007; 177: 1815–1819.

    Article  Google Scholar 

  6. Müller A, Mulhall JP . Sexual dysfunction in the patient with prostatitis. Curr Opin Urol 2005; 15: 404–409.

    Article  Google Scholar 

  7. Liang CZ, Zhang XJ, Hao ZY, Shi HQ, Wang KX . Prevalence of sexual dysfunction in Chinese men with chronic prostatitis. BJU Int 2004; 93: 568–570.

    Article  Google Scholar 

  8. Bushman W . Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 2009; 36: 403–415.

    Article  Google Scholar 

  9. Krieger JN, Nyberg Jr L, Nickel JC . NIH consensus definition and classification of prostatitis. JAMA 1999; 282: 236–237.

    Article  CAS  Google Scholar 

  10. Barry MJ, Fowler Jr FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al. The American Urological Association Symptom Index for benign prostatic hyperplasia.The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549–1557.

    Article  CAS  Google Scholar 

  11. Litwin MS, McNaughton-Collins M, Fowler Jr FJ, Nickel JC, Calhoun EA, Pontari MA et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999; 162: 369–375.

    Article  CAS  Google Scholar 

  12. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM . Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–326.

    Article  CAS  Google Scholar 

  13. McVary K . Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006; 97: 23–28.

    Article  Google Scholar 

  14. Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA . Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH registry. Urology 2009; 73: 562–566.

    Article  Google Scholar 

  15. Ying J, Yao D, Jiang Y, Ren X, Xu M . The positive effect of sildenafil on LUTS from BPH while treating ED. Zhonghua Nan Ke Xue 2004; 10: 681–683.

    PubMed  Google Scholar 

  16. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228–1234.

    Article  CAS  Google Scholar 

  17. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E . A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008; 53: 1236–1244.

    Article  CAS  Google Scholar 

  18. Liang CZ, Zhang XJ, Hao ZY, Shi HQ, Wang KX . Prevalence of sexual dysfunction in Chinese men with chronic prostatitis. BJU Int 2004; 93: 568–570.

    Article  Google Scholar 

  19. Tuncel A, Akbulut Z, Atan A, Basar MM . Common symptoms in men with prostatic inflammation. Int Urol Nephrol 2006; 38: 583–586.

    Article  Google Scholar 

  20. Turner JA, Hauge S, Von Korff M, Saunders K, Lowe M, Berger R . Primary care and urology patients with the male pelvic pain syndrome: symptoms and quality of life. J Urol 2002; 167: 1768–1773.

    Article  Google Scholar 

  21. Aubin S, Berger RE, Heiman JR, Ciol MA . The association between sexual function, pain, and psychological adaptation of men diagnosed with chronic pelvic pain syndrome type III. J Sex Med 2008; 5: 657–667.

    Article  Google Scholar 

  22. Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F et al. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 2009; 69: 1774–1780.

    Article  Google Scholar 

  23. Kramer G, Marberger M . Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006; 16: 25–29.

    PubMed  Google Scholar 

  24. Ozden C, Ozdal OL, Guzel O, Han O, Seckin S, Memis A . The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. Int Urol Nephrol 2007; 39: 859–863.

    Article  CAS  Google Scholar 

  25. Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS . The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008; 54: 1379–1384.

    Article  Google Scholar 

  26. Sprague AH, Khalil RA . Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009; 78: 539–552.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology Clinic, Dr Lütfi Kirdar Kartal Training and Research Hospital, Istanbul, Turkey

    B Eryildirim, A Aktas, U Kuyumcuoglu, G Faydaci, F Tarhan & A Ozgül

Authors
  1. B Eryildirim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Aktas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U Kuyumcuoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Faydaci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Tarhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Ozgül
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Eryildirim.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eryildirim, B., Aktas, A., Kuyumcuoglu, U. et al. The effectiveness of sildenafil citrate in patients with erectile dysfunction and lower urinary system symptoms and the significance of asymptomatic inflammatory prostatitis. Int J Impot Res 22, 349–354 (2010). https://doi.org/10.1038/ijir.2010.26

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2010.26

Keywords

This article is cited by

Search

Advanced search

Quick links